The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor StudiesBhavatarini Vangamudi, Jannik N. Andersen, Thomas A. Paul et al.|Cancer Research|2015Cited by 275
Lenalidomide and CC-4047 Inhibit the Proliferation of Malignant B Cells while Expanding Normal CD34+ Progenitor CellsDominique Verhelle, Kyle Chan, Laura G. Corral et al.|Cancer Research|2007Cited by 232
Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cellsLaure A Moutouh-de Parseval, Kyle Chan, Dominique Verhelle et al.|Journal of Clinical Investigation|2008Cited by 180
Pomalidomide and Lenalidomide Induce p21WAF-1 Expression in Both Lymphoma and Multiple Myeloma through a LSD1-Mediated Epigenetic MechanismLaure Escoubet‐Lozach, Dominique Verhelle, I-Lin Lin et al.|Cancer Research|2009Cited by 170
Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (<i>R</i>)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2<i>H</i>)-one (PF-06821497)Pei‐Pei Kung, Martin P. Edwards, Patrick Bingham et al.|Journal of Medicinal Chemistry|2017Cited by 129